Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COMVC-19: A Program to protect healthcare workers' mental health during the COVID-19 Pandemic. What we have learned.
Fukuti P, Uchôa CLM, Mazzoco MF, Cruz IDGD, Echegaray MVF, Humes EC, Silveira JB, Santi TD, Miguel EC, Corchs F; COMVC-19 program; Fatori D, Campello G, Oliveira GM, Argolo FC, Ferreira FM, Machado G, Argeu A, Oliveira GMR, Serafim AP, Siqueira LL, Rossi L, Rios IC, Oliveira TR, Antoniazzi LCK, Gagliotti DAM, Abelama Neto E, Oliveira Junior PN, Correia AV, Gonçalves LS, Tortato LS, Busato WMM, Guimarães-Fernandes F, Alves M, Leite Netto OF, Schoueri PCL, Roque MA, Merlin SS, Boer GCM, Sallet PC, Malbergier A, Spedo MA, Kamitsuji CS, Faria E, Moreira MVG, Kaufman A, Abdo C, Scanavino MT, Lancman S, Tavares H, Polanczyk G, Brunoni AR, Forlenza OV, Barros-Filho TEP. Fukuti P, et al. Among authors: echegaray mvf. Clinics (Sao Paulo). 2021 Nov 19;76:e2631. doi: 10.6061/clinics/2021/e2631. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34817044 Free PMC article.
Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial.
Vieira F, Correia-Melo FS, Santos-Lima C, Souza-Marques B, Leal GC, Jesus-Nunes AP, Mello RP, Caliman-Fontes AT, Bandeira ID, Marback RF, Telles M, Argolo FC, Lins-Silva DH, Echegaray MVF, Beanes G, Araújo-de-Freitas L, Silva SS, Cardoso TA, Kapczinski F, Turecki G, Lacerda ALT, Quarantini LC. Vieira F, et al. Among authors: echegaray mvf. Gen Hosp Psychiatry. 2021 Jan-Feb;68:97-99. doi: 10.1016/j.genhosppsych.2020.12.011. Epub 2020 Dec 20. Gen Hosp Psychiatry. 2021. PMID: 33376001 Clinical Trial. No abstract available.
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.
Correia-Melo FS, Leal GC, Carvalho MS, Jesus-Nunes AP, Ferreira CBN, Vieira F, Magnavita G, Vale LAS, Mello RP, Nakahira C, Argolo FC, Cardoso T, Souza CDS, Fontes ATC, Ferreira MB, Araújo-de-Freitas L, Tuena MA, Echegaray MVF, Cavalcanti DE, Lucchese AC, Bandeira ID, Telles M, Lima CS, Sampaio AS, Silva SS, Marback RF, Del-Porto JA, Abreu JN, Sarin LM, Paixão CS, Carvalho LP, Machado PRL, Turecki G, Lacerda ALT, Quarantini LC. Correia-Melo FS, et al. Among authors: echegaray mvf. Medicine (Baltimore). 2018 Sep;97(38):e12414. doi: 10.1097/MD.0000000000012414. Medicine (Baltimore). 2018. PMID: 30235716 Free PMC article. Clinical Trial.
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MVF, Bandeira ID, Silva SS, Cavalcanti DE, Araújo-de-Freitas L, Sarin LM, Tuena MA, Nakahira C, Sampaio AS, Del-Porto JA, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Correia-Melo FS, et al. Among authors: echegaray mvf. J Affect Disord. 2020 Mar 1;264:527-534. doi: 10.1016/j.jad.2019.11.086. Epub 2019 Nov 14. J Affect Disord. 2020. PMID: 31786030 Clinical Trial.
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Mello RP, Echegaray MVF, Jesus-Nunes AP, Leal GC, Magnavita GM, Vieira F, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Souza-Marques B, Bandeira ID, Santos-Lima C, Marback RF, Correia-Melo FS, Lacerda ALT, Quarantini LC. Mello RP, et al. Among authors: echegaray mvf. J Psychiatr Res. 2021 Jun;138:576-583. doi: 10.1016/j.jpsychires.2021.05.014. Epub 2021 May 8. J Psychiatr Res. 2021. PMID: 33991996 Clinical Trial.
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
Araújo-de-Freitas L, Santos-Lima C, Mendonça-Filho E, Vieira F, França RJAF, Magnavita G, Cardoso TL, Correia-Melo FS, Leal GC, Jesus-Nunes AP, Souza-Marques B, Marback R, Teles M, Echegaray MV, Beanes G, Guerreiro-Costa LNF, Mello RP, Rabanea T, Lucchese AC, Abreu N, Lacerda ALT, Quarantini LC. Araújo-de-Freitas L, et al. Psychiatry Res. 2021 Sep;303:114058. doi: 10.1016/j.psychres.2021.114058. Epub 2021 Jun 7. Psychiatry Res. 2021. PMID: 34153630 Clinical Trial.
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixão CS, Carvalho MS, Jesus-Nunes AP, Vieira F, Magnavita G, Bandeira ID, Mello RP, Beanes G, Silva SS, Echegaray M, Carvalho LP, Machado P, Sampaio AS, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Caliman-Fontes AT, et al. Trends Psychiatry Psychother. 2023;45:e20210298. doi: 10.47626/2237-6089-2021-0298. Epub 2023 Mar 7. Trends Psychiatry Psychother. 2023. PMID: 34904800 Free PMC article. Clinical Trial.
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP, Leal GC, Correia-Melo FS, Vieira F, Mello RP, Caliman-Fontes AT, Echegaray MVF, Marback RF, Guerreiro-Costa LNF, Souza-Marques B, Santos-Lima C, Souza LS, Bandeira ID, Kapczinski F, Lacerda ALT, Quarantini LC. Jesus-Nunes AP, et al. Among authors: echegaray mvf. Hum Psychopharmacol. 2022 Jul;37(4):e2836. doi: 10.1002/hup.2836. Epub 2022 Feb 18. Hum Psychopharmacol. 2022. PMID: 35179810 Clinical Trial.
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
Echegaray MVF, Mello RP, Magnavita GM, Leal GC, Correia-Melo FS, Jesus-Nunes AP, Vieira F, Bandeira ID, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Marback RF, Souza-Marques B, Lins-Silva DH, Santos-Lima C, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Echegaray MVF, et al. Trends Psychiatry Psychother. 2023 Sep 17. doi: 10.47626/2237-6089-2022-0593. Online ahead of print. Trends Psychiatry Psychother. 2023. PMID: 37717263 Free article.